GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codiak BioSciences Inc (OTCPK:CDAKQ) » Definitions » Degree of Financial Leverage

Codiak BioSciences (Codiak BioSciences) Degree of Financial Leverage : 0.00 (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Codiak BioSciences Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Codiak BioSciences's Degree of Financial Leverage for the quarter that ended in Sep. 2022 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Codiak BioSciences's Degree of Financial Leverage or its related term are showing as below:

CDAKQ's Degree of Financial Leverage is not ranked *
in the Biotechnology industry.
Industry Median: 0.96
* Ranked among companies with meaningful Degree of Financial Leverage only.

Codiak BioSciences Degree of Financial Leverage Historical Data

The historical data trend for Codiak BioSciences's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codiak BioSciences Degree of Financial Leverage Chart

Codiak BioSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Degree of Financial Leverage
- - 0.58 1.17

Codiak BioSciences Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.83 1.17 1.15 1.03 1.03

Competitive Comparison of Codiak BioSciences's Degree of Financial Leverage

For the Biotechnology subindustry, Codiak BioSciences's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codiak BioSciences's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codiak BioSciences's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Codiak BioSciences's Degree of Financial Leverage falls into.



Codiak BioSciences Degree of Financial Leverage Calculation

Codiak BioSciences's Degree of Financial Leverage for the quarter that ended in Sep. 2022 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.69 (Sep. 2022) / -3.61 (Sep. 2021) - 1 )/( -14.807 (Sep. 2022) / -68.975 (Sep. 2021) - 1 )
=-0.8089/-0.7853
=1.03***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Codiak BioSciences  (OTCPK:CDAKQ) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Codiak BioSciences Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Codiak BioSciences's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Codiak BioSciences (Codiak BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
35 Cambridge Park Drive, Suite 500, Cambridge, MA, USA, 02140
Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.
Executives
Yalonda Howze officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Sriram Sathyanarayanan officer: Chief Scientific Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Nicole Barna officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Douglas E Williams director, officer: President & CEO C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Linda Bain officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Konstantin Konstantinov officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David J Mauro officer: Chief Medical Officer 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Arundathy N. Pandite director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Benny Sorensen officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Anne-virginie Eggimann director C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Jennifer J. Wheler officer: Chief Medical Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Alaska Permanent Fund Corp 10 percent owner 801 WEST 10TH STREET, SUITE 302, JUNEAU AK 99801
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142

Codiak BioSciences (Codiak BioSciences) Headlines